Osteopontin as an Adjunct to CA125 in Detecting Recurrent Ovarian Cancer

Schorge, John O.; Drake, Richard D.; Lee, Hang; Skates, Steven J.; Rajanbabu, Ramababu; Miller, David S.; Kim, Jae-Hoon; Cramer, Daniel W.; Berkowitz, Ross S.; Mok, Samuel C.

doi:10.1158/1078-0432.ccr-03-0365

Cited by 83 publications

(67 citation statements)

References 26 publications

(19 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…9 Other biomarkers, including human kallikrein, HE4 and osteopontin, are under investigation and large screening trials are underway in the United Kingdom. [10][11][12][13] Efforts to use multiple biomarkers, although encouraging, have met with mixed results. One study comparing the serologic detection of multiple biomarkers demonstrated comparable sensitivity (79% and 82%) and an improvement in specificity from 68% to 88%.…”

Section: Early Detection Of Ovarian Cancermentioning

confidence: 99%

Lessons from BRCA: The Tubal Fimbria Emerges as an Origin for Pelvic Serous Cancer

Crum¹,

Drapkin²,

Kindelberger³

et al. 2007

Clinical Medicine & Research

313

219

View full text Add to dashboard Cite

Ovarian epithelial cancer is diagnosed in approximately 25,000 women yearly in the United States, accounting for approximately 12,500 deaths. Of these tumors, serous cancer is the most lethal, due to its capacity to spread beyond the reproductive tract and involve the peritoneal surfaces or distant organs. Conventional classification systems designate tumor origins principally on the location of the largest tumor. However, despite the fact that the largest tumors typically involve the ovaries, demonstrations of a precise starting point for these tumors, including precursor lesions, have been inconsistent. In recent years, a major effort to prevent serous cancer in genetically susceptible women with mutations in BRCA1 or BRCA2 has spawned the practice of prophylactic salpingo-oophorectomy. This practice has surprisingly revealed that many early cancers in these women arise in the fallopian tube, and further studies have pinpointed the distal (fimbrial) portion as the most common site of origin. Emerging studies that carefully examine the fallopian tubes suggest a high frequency of early cancer in the fimbria in unselected women with ovarian and peritoneal serous carcinoma, raising the distinct possibility that a significant proportion of these tumors have a fimbrial origin.The evidence for these discoveries and their relevance to serous cancer classification, early detection and prevention are addressed in this review. A model for pelvic serous cancer is proposed that takes into account five distinct variables which ultimately impact on origin and tumor distribution: (1) location of target epithelium, (2) genotoxic stress, (3) type of epithelium, (4) mitigating genetic factors, and (5) tumor spread pattern. Ultimately, this model illustrates the importance of identifying cancer precursors, inasmuch as these entities are useful as both surrogate endpoints for their respective malignancies in epidemiologic studies and natural targets for cancer prevention. Ovar ian epithelial cancer is diagnosed in approximately 25,000 women yearly in the United States with approximately one half dying of their disease. 1 It typically afflicts women near to menopause or postmenopause and peaks in the sixth to seventh decades of life. Surgery and chemotherapy will produce a complete response in 70% of patients; however, relapse rates are high, often occurring after a relatively brief respite. Overall long-term survival, but not cure, rates have only begun to improve measurably with the advent of taxol chemotherapy and intraperitoneal routes of instillation. However, the incremental gain in disease-free survival seen with these new therapies is only a few months. 2 Approximately 10% of women with ovarian cancer have a positive family history and most have an inherited heterozygous mutation in the BRCA1 or BRCA2 gene. Women with a hereditary predisposition for ovarian cancer develop the disease on average a decade earlier. 3,4 The lifetime risk of ovarian cancer in women with mutations in BRCA1 or BRCA2 (BRCA+) is estimated to be as h...

show abstract

Section: Early Detection Of Ovarian Cancermentioning

confidence: 99%

Lessons from BRCA: The Tubal Fimbria Emerges as an Origin for Pelvic Serous Cancer

Crum¹,

Drapkin²,

Kindelberger³

et al. 2007

Clinical Medicine & Research

313

219

View full text Add to dashboard Cite

show abstract

“…Osteopontin has long been implicated in the process of carcinogenesis, progression, and metastatic dissemination of several human tumors including lung cancer [14][15][16][17][18][19][20][21][22] . This study evaluated the association of circulating osteopontin levels with tumor progression using clinical samples from the patients who underwent surgical resection and mediastinal lymphadenectomy for their NSCLC and have taken no any anti-cancer therapy till time of sampling.…”

Section: Discussionmentioning

confidence: 99%

Elevated circulating levels of osteopontin are associated with metastasis in advanced non-small cell lung cancer

Chen

et al. 2011

Chin. J. Cancer Res.

View full text Add to dashboard Cite

Objective: To investigate the relationship between postoperative metastasis and circulating levels of osteopontin in non-small cell lung cancer (NSCLC).Methods: The expression of osteopontin mRNA were detected with RT-PCR technique. The circulating levels of osteopontin were measured through ELASA in 46 NSCLC cases that had not been received any anti-cancer treatment at the time of sampling. The tissues from fifteen patients with benign pulmonary diseases were studied as control group.Results: The overall median mRNA expression level of osteopontin was approximately 70-fold higher in tumor tissues than in matched normal lung tissues (P<0.001). Over-expression of osteopontin mRNA was significantly associated with clinical stage (P=0.009). Advanced disease states had higher circulating level of osteopontin (stage I+II versus stage III+VI). In multivariate analysis, stage was the only independent factor influencing circulating levels of osteopontin. All patients were followed up for 12 months, 2 of the 46 patients with both osteopontin mRNA expression and elevated plasma osteopontin levels had local recurrence and 10 had distant metastasis. There was a significant difference in the osteopontin levels between metastasis group and non-metastasis group.Conclusion: Preoperative plasma levels of osteopontin are significantly associated with post-operative metastasis in advanced NSCLC.

show abstract

“…In an additional study, an elevated serum CA125 (≥35 units/mL) and preoperative ultrasound findings of solid or complex tumors yielded a PPV of 84.7%, a NPV of 92.4% and correctly identified 77.3% of patients with early stage disease 70 . Additional potential serum biomarkers have been identified [72][73][74] and extensively examined for the detection of ovarian cancer [75][76][77] . Human epididymis protein 4 (HE4) is a biomarker overexpressed by both serous and endometrioid ovarian cancers 78 and is expressed by 32% of ovarian cancers lacking CA125 expression 76 .…”

Section: What Role Do Biomarkers Play In the Screening Of Ovarian Canmentioning

confidence: 99%

Preventive Strategies in Epithelial Ovarian Cancer

Mantia‐Smaldone¹,

Scholler²

2012

Ovarian Cancer - Clinical and Therapeutic Perspectives

View full text Add to dashboard Cite

Osteopontin as an Adjunct to CA125 in Detecting Recurrent Ovarian Cancer

Cited by 83 publications

References 26 publications

Lessons from BRCA: The Tubal Fimbria Emerges as an Origin for Pelvic Serous Cancer

Lessons from BRCA: The Tubal Fimbria Emerges as an Origin for Pelvic Serous Cancer

Elevated circulating levels of osteopontin are associated with metastasis in advanced non-small cell lung cancer

Preventive Strategies in Epithelial Ovarian Cancer

Contact Info

Product

Resources

About